BACKGROUND AND PURPOSE: Bradykinin, through its B(2) receptor, is involved in inflammatory processes related to arthropathies. In carrageenan and lipopolysaccharide (LPS)-induced arthritis in rat, the anti-inflammatory activity of MEN16132, a potent and selective kinin B(2) receptor antagonist, was compared with that of steroidal and nonsteroidal anti-inflammatory drugs. The interaction between MEN16132 and dexamethasone was also investigated. EXPERIMENTAL APPROACH: Drugs, alone or in combination, were injected into the knee joint 30min before intra-articular administration of carrageenan or LPS, in pentobarbital anaesthetized rats. Effects on incapacitation, oedema, neutrophil recruitment and kallikrein system activation, in the knee joint, were assessed. KEY RESULTS: MEN16132 and dexamethasone (10-300µg per knee) dose-dependently reduced carrageenan-induced joint pain, oedema and neutrophil infiltration, reaching a maximal inhibition of about 50%. Dexketoprofen exerted a similar analgesic activity, whereas it did not affect the other inflammatory responses. MEN16132 showed a partial inhibition of LPS-induced joint pain, whereas dexamethasone produced a full analgesic effect. Combination of MEN16132 and dexamethasone showed a strong synergistic interaction in inhibiting both carrageenan and LPS-induced knee joint inflammation. Dexamethasone did not prevent the contact activation of prekallikrein by carrageenan and the subsequent release of kallikreins and bradykinin in the synovium. CONCLUSIONS AND IMPLICATIONS: Steroids and kinin B(2) receptor antagonists appear to relieve arthritic symptoms induced by carrageenan or LPS and act synergistically to inhibit joint inflammation. This could have interesting therapeutic implications, possibly opening the way for combination therapies in the control of inflammatory arthropathies.
BACKGROUND AND PURPOSE: Bradykinin, through its B(2) receptor, is involved in inflammatory processes related to arthropathies. In carrageenan and lipopolysaccharide (LPS)-induced arthritis in rat, the anti-inflammatory activity of MEN16132, a potent and selective kinin B(2) receptor antagonist, was compared with that of steroidal and nonsteroidal anti-inflammatory drugs. The interaction between MEN16132 and dexamethasone was also investigated. EXPERIMENTAL APPROACH: Drugs, alone or in combination, were injected into the knee joint 30min before intra-articular administration of carrageenan or LPS, in pentobarbital anaesthetized rats. Effects on incapacitation, oedema, neutrophil recruitment and kallikrein system activation, in the knee joint, were assessed. KEY RESULTS:MEN16132 and dexamethasone (10-300µg per knee) dose-dependently reduced carrageenan-induced joint pain, oedema and neutrophil infiltration, reaching a maximal inhibition of about 50%. Dexketoprofen exerted a similar analgesic activity, whereas it did not affect the other inflammatory responses. MEN16132 showed a partial inhibition of LPS-induced joint pain, whereas dexamethasone produced a full analgesic effect. Combination of MEN16132 and dexamethasone showed a strong synergistic interaction in inhibiting both carrageenan and LPS-induced knee joint inflammation. Dexamethasone did not prevent the contact activation of prekallikrein by carrageenan and the subsequent release of kallikreins and bradykinin in the synovium. CONCLUSIONS AND IMPLICATIONS: Steroids and kinin B(2) receptor antagonists appear to relieve arthritic symptoms induced by carrageenan or LPS and act synergistically to inhibit joint inflammation. This could have interesting therapeutic implications, possibly opening the way for combination therapies in the control of inflammatory arthropathies.
Authors: Johannes W J Bijlsma; Amalia A Van Everdingen; Margriet Huisman; Ron N J T L De Nijs; Johannes W G Jacobs Journal: Ann N Y Acad Sci Date: 2002-06 Impact factor: 5.691
Authors: J N Francischi; C T Chaves; A C L Moura; A S Lima; O A Rocha; D L Ferreira-Alves; Y S Bakhle Journal: Br J Pharmacol Date: 2002-11 Impact factor: 8.739
Authors: L M Fredrik Leeb-Lundberg; Francois Marceau; Werner Müller-Esterl; Douglas J Pettibone; Bruce L Zuraw Journal: Pharmacol Rev Date: 2005-03 Impact factor: 25.468
Authors: S Meini; P Cucchi; L Tinti; S Niccolini; F Bellucci; C Catalani; C Valenti; M Galeazzi; A Fioravanti; C A Maggi Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2012-05-26 Impact factor: 3.000
Authors: Vanessa Lima Cavalcante de Oliveira; José Antonio Silva; Andrey Jorge Serra; Rodney Capp Pallotta; Evela Aparecida Pereira da Silva; Anna Cristina de Farias Marques; Regiane Dos Santos Feliciano; Rodrigo Labat Marcos; Ernesto Cesar Pinto Leal-Junior; Paulo de Tarso Camillo de Carvalho Journal: Lasers Med Sci Date: 2016-10-10 Impact factor: 3.161